A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.
Qing LiuYanni LouLiya LiGuowang YangHuijuan CuiZhiqiang ChengYuan LiMeng LiuChao DengDonggui WanYongxia YanLiqun JiaPublished in: Integrative cancer therapies (2022)
DCVAC/LuCa, combined with standard of care chemotherapy and Shenqi Fuzheng injection exhibited good benefit in Chinese patients with recurrent metastatic or advanced (stage IIIB/IV) NSCLC, and also significantly improved Qi insufficiency constitution. There were no related adverse events with DCVAC/LuCa treatment.
Keyphrases
- phase ii study
- locally advanced
- healthcare
- small cell lung cancer
- palliative care
- squamous cell carcinoma
- quality improvement
- rectal cancer
- open label
- ultrasound guided
- radiation therapy
- single cell
- pain management
- affordable care act
- stem cells
- advanced non small cell lung cancer
- clinical trial
- chemotherapy induced
- tyrosine kinase